Does intravesical atropine have equivalent efficacy to oral oxybutynin in the treatment of detrusor overactivity?
Amy M Arisco and Stephen R Kraus*
Correspondence *Section of Female Urology, Neuro-Urology & Voiding Dysfunction, Department of Urology, University of Texas Health Science Center, 7703 Floyd Curl Drive, MC 7845, San Antonio, TX 78229-3900, USA
Email krauss@uthscsa.edu
This article has no abstract so we have provided the first paragraph of the full text.
The treatment of detrusor overactivity (DO) represents a particularly difficult challenge in the patient with a neurogenic bladder caused by MS. The symptoms of overactive bladder (OAB) are not uncommon in patients with MS. This, and the additional risk to the upper urinary tract, often warrants aggressive treatment with antimuscarinic drugs.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.